Astellas Pharma

AviadoBio is a biotechnology company focused on developing transformative gene therapies for neurodegenerative disorders, specifically targeting diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages innovative research from King’s College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a deep understanding of brain biology with proprietary gene therapies, AviadoBio aims to effectively address the challenges of delivering treatments to the appropriate areas within the nervous system. The ultimate goal is to enhance the therapeutic potential of gene therapy, potentially halting or even reversing the progression of these debilitating conditions, thereby improving the quality of life for affected individuals.

Propella Therapeutics is a development-stage biopharmaceutical company focused on creating innovative prescription products that leverage known active ingredients with validated mechanisms of action. The company employs advanced medicinal chemistry and lymphatic targeting techniques to develop oncology drugs that enhance bioavailability to critical tissues, such as lymph nodes and bone metastatic sites. This approach aims to improve pharmacological activity while minimizing adverse effects on the liver and enhancing the overall safety profile of the drugs. By utilizing established active ingredients, Propella Therapeutics seeks to bring best-in-class therapies to market, addressing significant needs in cancer treatment.

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapeutics for patients with significant unmet medical needs. The company specializes in genome engineering technologies and is focused on creating targeted treatments, including a pipeline of autologous and allogeneic chimeric antigen receptor T cell (CAR-T) therapies aimed at addressing hematological malignancies and solid tumors. Additionally, Poseida is advancing gene therapies for rare and life-threatening diseases, such as Ornithine transcarbamylase deficiency and methylmalonic acidemia, along with therapies for genetic liver diseases. Founded in 2014, Poseida Therapeutics is committed to improving patient outcomes through its cutting-edge research and development efforts.

IVERIC bio is a biopharmaceutical company dedicated to discovering and developing innovative treatments for retinal diseases that have significant unmet medical needs. The company is actively working on therapeutic product candidates aimed at age-related retinal diseases, as well as gene therapy product candidates designed for orphan inherited retinal diseases. By focusing on these areas, IVERIC bio aims to address critical gaps in the current treatment landscape for patients suffering from various retinal conditions.

Taysha Gene Therapies, Inc. is a gene therapy company based in Dallas, Texas, focused on developing adeno-associated virus (AAV)-based therapies for monogenic diseases of the central nervous system (CNS). Founded in 2019, the company aims to create curative treatments for severe and life-threatening conditions. Its pipeline includes several product candidates, such as TSHA-101 for GM2 gangliosidosis, TSHA-118 for CLN1 disease, TSHA-102 for Rett syndrome, TSHA-103 for SLC6A1 haploinsufficiency disorder, and TSHA-104 for Surfeit locus 1 deficiency. Taysha collaborates with The University of Texas Southwestern Medical Center to enhance its development and commercialization efforts, leveraging expertise in gene therapy to advance its mission of eradicating monogenic CNS diseases.

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 26 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. World-renowned experts from NCCN Member Institutions diagnose and treat patients with a broad spectrum of cancers and are recognized for dealing with complex, aggressive, or rare cancers. NCCN Member Institutions pioneered the concept of the multidisciplinary team approach to patient care and conduct innovative research that contributes significantly to understanding, diagnosing, and treating cancer. NCCN programs offer access to expert physicians, superior treatment, and quality and safety initiatives that continuously improve the effectiveness and efficiency of cancer care.

Iota Biosciences, Inc. is a medical device company based in Berkeley, California, founded in 2017. The company specializes in developing innovative bioelectronic devices that utilize wireless sensors to monitor, measure, and stimulate internal nerves, muscles, and organs for electroceutical applications aimed at treating immune and neural disorders. Iota's technology is built on pioneering ultrasound advancements from the University of California, Berkeley, and includes implantable, mote-sized ultrasonic sensors that facilitate completely wireless neural recordings. This approach eliminates the need for tethered connections, allowing for real-time monitoring and improved treatment of diseases. As a subsidiary of Astellas Pharma Inc., Iota Biosciences is committed to delivering safe and effective diagnostic and therapeutic solutions that transform disease management and significantly enhance patient care.

Nanna Therapeutics Limited, established in 2012 and headquartered in Cambridge, UK, is a biotechnology company focused on developing drugs for age-related diseases such as mitochondrial, neurodegenerative, cardiovascular/metabolic, joint/tissue diseases, and cancer. As of April 2020, the company operates as a subsidiary of Astellas Pharma Europe Ltd. Nanna Therapeutics employs a unique approach by targeting fundamental cellular processes to create innovative treatments for these conditions, with a particular emphasis on mitochondria, the energy source in every cell. The company's proprietary drug discovery platform, TIME (Totally Integrated Medicines Engine), combines advanced technologies like microfluidics and artificial intelligence to accelerate drug development and disrupt traditional methods of creating new medicines.

Xyphos Biosciences, Inc. is a biotechnology company based in South San Francisco, California, specializing in the development of immuno-oncology therapeutics aimed at enhancing the patient's immune response to combat cancer. Founded in 2004, the company has created a CAR-T cell therapy platform known as ACCEL (Advanced Cellular Control through Engineered Ligands), which allows for precise control and targeting of immune cells to treat relapsed hematological malignancies and solid tumors. This platform features convertibleCAR-T cells that can be directed using any tumor-specific full antibody, providing critical functionalities that enhance their effectiveness. Xyphos Biosciences focuses on employing uniquely modified human receptors that can be selectively activated with bispecific antibody-like molecules, enabling targeted destruction of cancer cells and offering the potential for durable cures while minimizing the risk of tumor recurrence. As of December 2019, Xyphos operates as a subsidiary of Astellas Pharma Inc.

Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

LabCentral is a provider of business incubation and acceleration services designed to support startup entrepreneurs in the life sciences sector. The company offers a range of services, including mentorship, coaching, and access to specialized workspaces, facilitating an environment where innovative biotech startups can thrive. LabCentral also organizes promotional events to connect entrepreneurs with potential investors, helping them secure funding and grow their businesses. By fostering collaboration and providing essential resources, LabCentral plays a crucial role in advancing the development of novel treatments and technologies within the life sciences industry.

Iota Biosciences, Inc. is a medical device company based in Berkeley, California, founded in 2017. The company specializes in developing innovative bioelectronic devices that utilize wireless sensors to monitor, measure, and stimulate internal nerves, muscles, and organs for electroceutical applications aimed at treating immune and neural disorders. Iota's technology is built on pioneering ultrasound advancements from the University of California, Berkeley, and includes implantable, mote-sized ultrasonic sensors that facilitate completely wireless neural recordings. This approach eliminates the need for tethered connections, allowing for real-time monitoring and improved treatment of diseases. As a subsidiary of Astellas Pharma Inc., Iota Biosciences is committed to delivering safe and effective diagnostic and therapeutic solutions that transform disease management and significantly enhance patient care.

Potenza Therapeutics, Inc. is a preclinical-stage biotechnology company based in Cambridge, Massachusetts, established in 2014. The company is dedicated to developing a portfolio of oncology programs that harness the body's immune system to identify and eliminate tumors. Potenza's innovative approach focuses on understanding the mechanisms that allow cancer cells to evade immune detection and destruction. By leveraging these biological insights, the company aims to create effective and reliable therapeutic solutions that enhance patient health and improve cancer treatment outcomes.

Quethera Limited is a biotechnology company based in Canterbury, United Kingdom, focused on developing gene therapy treatments for glaucoma and other ophthalmic diseases. Established in 2013, the company aims to address progressive visual loss associated with these conditions, particularly in patients experiencing accelerated deterioration of their visual fields. Quethera collaborates with leading experts in the field of glaucoma to design and conduct clinical trials that assess the efficacy and safety of its innovative therapies. With a strong foundation in gene therapeutic design and development, Quethera is advancing its pipeline from preclinical testing into clinical development, striving to provide effective treatment solutions for common blinding eye diseases. As of 2018, Quethera operates as a subsidiary of Astellas Pharma Inc.

Heartseed Inc. is a Tokyo-based biotechnology company founded in 2015, focused on developing myocardial regeneration medicine utilizing induced pluripotent stem (iPS) cells. The company's mission is to advance treatments for heart disease through regenerative medicine, specifically targeting advanced heart failure with iPS cell-derived cardiomyocyte replacement therapy. Heartseed aims to enable the clinical application of its innovative therapies to improve outcomes for patients suffering from heart conditions.

Universal Cells Inc. is a biotechnology company based in Seattle, Washington, specializing in the development, licensing, and commercialization of stem cell therapies. Founded in 2013, the company focuses on creating universal donor stem cells that are compatible with all patients, eliminating the need for HLA-matching and reducing the risk of donor tissue rejection. Universal Cells employs proprietary genome editing technology, specifically recombinant adeno-associated virus-mediated gene editing, to engineer stem cells by preventing the expression of polymorphic human leukocyte antigen (HLA) molecules. This innovative approach allows for the production of off-the-shelf therapeutic products and facilitates the advancement of cell therapies for a variety of diseases and conditions. As of February 2018, Universal Cells operates as a subsidiary of Astellas Pharma Inc.

Mitobridge, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing small molecule therapeutics that enhance mitochondrial function. The company aims to address diseases associated with mitochondrial dysfunction, including genetic, metabolic, and neurodegenerative disorders, as well as age-related conditions. One of its key pipeline products is MA-0211, an orally bioavailable PPARd modulator designed to reverse mitochondrial deficits in patients with Duchenne muscular dystrophy. Founded in 2013 and formerly known as Mitokyne, Inc., Mitobridge operates with a strategy that emphasizes establishing proof of concept in rare diseases before expanding into more prevalent conditions. The company has assembled a team of experts in mitochondrial biology and related fields, with a commitment to advancing innovative therapeutics into clinical settings. As of early 2018, Mitobridge operates as a subsidiary of Astellas Pharma Inc.

Catalia Health Inc. is a San Francisco-based company that specializes in developing a cloud-based patient care management platform. Founded in 2014, Catalia Health combines artificial intelligence, psychology, and medicine to enhance patient engagement and provide valuable data to healthcare providers. Its innovative platform facilitates real-time communication with patients, addressing their ongoing healthcare issues through personalized conversations. These interactions occur via mobile apps, a web interface, and a patented interactive robotic coach, allowing healthcare professionals to monitor patient progress and adherence to treatment effectively. By delivering tailored medical support and psychological assistance, Catalia Health aims to improve patient outcomes within pharmaceuticals, healthcare systems, and assisted living facilities.

Ogeda SA is a clinical-stage drug discovery company based in Gosselies, Belgium, that specializes in the invention and development of small molecule drugs targeting G-Protein Coupled Receptors (GPCRs). Founded in 1994 and formerly known as Euroscreen, the company focuses on developing innovative therapies for women's health disorders, with its lead product, fezolinetant, currently in Phase II clinical development. In addition to fezolinetant, Ogeda is advancing other small molecules aimed at treating various endocrine, central nervous system, and inflammatory conditions. The company maintains facilities in Brussels and Paris, and operates as a subsidiary of Astellas Pharma Inc. Through its research, Ogeda seeks to provide effective treatment options for hormone-dependent pathologies and other related health issues.

Ganymed Pharmaceuticals AG is a biopharmaceutical company with the mission of revolutionizing cancer treatment by developing a new class of therapeutic drugs called Ideal Monoclonal Antibodies (IMABs). IMABs are unique in that they are highly selective for proteins which are present on tumor cells, but do not bind to healthy cells. This unmatched tumor cell specificity makes IMABs cancer cell selective allowing them to efficiently kill tumor cells without harming normal healthy tissues. They can thus be administered at optimal dose and have a broad therapeutic window with reduced risks of side effects.

Ocata Therapeutics, Inc. is a clinical stage biotechnology company that specializes in developing and commercializing regenerative therapies for ophthalmic conditions. The company is focused on creating innovative treatments for diseases such as Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration, with its most advanced products currently undergoing clinical trials. Ocata possesses a robust intellectual property portfolio that includes pluripotent stem cell platforms, specifically human embryonic stem cells and induced pluripotent stem cells, alongside other research initiatives in cell therapy.

Mitobridge, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on discovering and developing small molecule therapeutics that enhance mitochondrial function. The company aims to address diseases associated with mitochondrial dysfunction, including genetic, metabolic, and neurodegenerative disorders, as well as age-related conditions. One of its key pipeline products is MA-0211, an orally bioavailable PPARd modulator designed to reverse mitochondrial deficits in patients with Duchenne muscular dystrophy. Founded in 2013 and formerly known as Mitokyne, Inc., Mitobridge operates with a strategy that emphasizes establishing proof of concept in rare diseases before expanding into more prevalent conditions. The company has assembled a team of experts in mitochondrial biology and related fields, with a commitment to advancing innovative therapeutics into clinical settings. As of early 2018, Mitobridge operates as a subsidiary of Astellas Pharma Inc.

Telsar Pharma Inc., a new company that will develop an Astellas drug for a common inflammatory bowel disease.

OSI Pharmaceuticals strives to improve the health and quality of life for patients, develop breakthrough treatment options for physicians, offer rewarding careers to employees, and deliver value to our shareholders. The strategy is to build on the success of our flagship product, Tarceva® (erlotinib), and continue to invest in clinical and pre-clinical drug candidates in oncology, diabetes and obesity to provide longer-term growth. OSI has evolved to become a scientifically strong and financially successful top-tier biopharmaceutical company that is focused on disease areas that impact virtually every family in the world. The Oncology team is dedicated to the discovery and development of molecular targeted therapies to revolutionize the way cancer is treated and improve treatment outcomes. The Diabetes & Obesity team is dedicated to the discovery and development of novel drugs for the treatment of type 2 diabetes and obesity. The strategy for this business team is to advance a pipeline of innovative diabetes and obesity research projects through clinical proof-of-concept studies, with a view to then potentially seeking financially attractive development and commercialization partnerships for these research programs. The goal is to pave the way for the future of oncology, diabetes and obesity treatments. They believe that our Company strategy is poised to deliver a rich pipeline of promising drug candidates that have the potential to significantly improve the treatment options available to patients today.

Agensys is a biotechnology company focused on the research and development of therapeutic human monoclonal antibodies and antibody-drug conjugates specifically aimed at treating various types of cancer. Founded in 1997 and based in Santa Monica, California, Agensys develops innovative products targeting tumors, including those associated with prostate, pancreatic, bladder, kidney, lung, and colon cancers. The company is dedicated to providing effective treatment options for patients battling these cancers. In 2007, Agensys became a subsidiary of Astellas Pharma US, Inc., further enhancing its capabilities in the oncology therapeutic space.